Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 4/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322127 | 1.00 | EPHX1 (0.39) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL7271811 | 0.98 | EPHX1 (0.42) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL9433734 | 0.98 | EPHX1 (0.42) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL1319123 | 0.96 | EPHX1 (0.35) | EPHX1NAAAHTTOPRK1CYP2C19 | |
| SCHEMBL1319121 | 0.96 | EPHX1 (0.35) | EPHX1NAAAHTTOPRK1CYP2C19 | |
| SCHEMBL11050292 | 0.92 | ATM (0.31) | — | |
| SCHEMBL11562387 | 0.83 | EPHX1 (0.39) | EPHX1NAAAHTTCA12CA1 | |
| SCHEMBL7427690 | 0.83 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL7427693 | 0.83 | OPRK1 (0.38) | OPRK1 | |
| SCHEMBL29882892 | 0.82 | EPHX2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-5276150-A | Vasodilators, anticoagulants, calcium channel blockers | FUJIREBIO INC. (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0400660-A1 | 1,4-dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1990-12-05 | — | — | EP | disclosed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | disclosed |
| US-4686217-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | FISONS PLC (GB) | 1987-08-11 | — | — | US | disclosed |
| US-4558058-A | HYPOTENSIVE AGENTS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1985-12-10 | — | — | US | disclosed |
| EP-0125803-A2 | Pharmaceutically active dihydropyridines | FISONS plc (GB) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | RYR1, RYR2, CACNA1S | EPHX1 668/4885NAAA 3269/4885HTT 1573/4885 |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | RYR1, TNNI3, RYR2 | EPHX1 695/4885NAAA 3913/4885HTT 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.